Efficacy and safety of once-daily IND-MF in symptomatic adult and adolescent patients with inadequately controlled asthma: findings from the Phase III randomized QUARTZ study

Introduction: GINA recommends ICS/LABA as initial controller therapy in inadequately controlled asthma patients (pts) on low-dose ICS. We evaluated efficacy and safety of low-dose indacaterol acetate/mometasone furoate (IND/MF) 150/80 µg once daily (o. d.) via Breezhaler® versus MF 200 µg o. d. via Twisthaler® in symptomatic asthma pts.